COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff. Learn more about attendance requirements for live courses and conferences and available COVID-19 online education and resources.
Akcea - Exhibitor

 

Company Website

Contact Information:

Trent Miller - Minnesota
tmiller@akceatx.com
952-300-5156

Kaitlin Camp - Arizona
505-459-4549
Kcamp@akceatx.com

Virtual Exhibit Hall Home

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, is a biopharmaceutical company headquartered in Boston, Massachusetts focused on developing and commercializing medicines to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI® (inotersen) in the U.S., E.U., Canada and Brazil, and WAYLIVRA® (volanesorsen) in the E.U., as well as advancing a mature pipeline of novel medicines, pelacarsen (AKCEA-APO(a)-LRx), vupanorsen (AKCEA-ANGPTL3-LRx), AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, with the potential to treat multiple diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology. Additional information is available at www.akceatx.com.

Additional Information
Consideration Brochure
Medication Guide
Leave Behind